You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
7 September 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) said on Monday that US regulators have granted accelerated approval for Etcamah (camizestrant), its next-generation oral selective oestrogen receptor degrade...
7 September 2026 - RNA therapy company Ionis Pharmaceuticals Inc (Nasdaq: IONS) disclosed on Monday that its partner Novartis reported topline results from the Phase 3 Lp(a)HORIZON study and said pelacarsen did not meet its primary endpoint of reduci...
7 September 2026 - Aptar Pharma, a provider of drug delivery, dosing, protection technologies and services and part of AptarGroup Inc (NYSE:ATR), announced on Monday that it has partnered with Aceso Therapeutics, a biotech developing novel therapies ...
7 September 2026 - Precision oncology company Guardant Health Inc (Nasdaq:GH) announced on Friday that the US Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH (camizestrant) in p...
7 September 2026 - Synthetic DNA 4basebio PLC (AIM: 4BB) declared on Monday that it has expanded its DNA offering to support production of critical starting material for personalised mRNA medicines.The expanded offering across the company's high...
7 September 2026 - Chinese biotechnology company Clover Biopharmaceuticals Ltd (HKEX:02197) announced on Sunday positive preliminary data from a Phase 2 clinical trial in older adults in Australia evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + ...
7 September 2026 - Rznomics Inc (KOSDAQ: 476830), a South Korea-based biopharmaceutical company specialising in the development of RNA-based gene therapies, on Monday announced a breakthrough in the high-efficiency production of circular RNA (circRNA...